| Patents for A61P 15 - Drugs for genital or sexual disorders; Contraceptives (55,635) |
|---|
| 07/22/2003 | US6596763 Method for counteracting infections caused by bacteria, fungi or virus such as Herpes Simplex Virus in skin or mucosal membranes, in particular genital membranes, of a mammal. The method comprises topically administering to skin or mucous |
| 07/22/2003 | US6596753 Compounds of the indolecarboxylic family and use thereof |
| 07/22/2003 | US6596749 Neuropeptide y receptor ligand |
| 07/22/2003 | US6596745 Method for treating fibrotic diseases with azolium chroman compounds |
| 07/22/2003 | US6596732 1,3-dihydro-2h-indol-2-one, preparation method and pharmaceutical compositions containing same |
| 07/22/2003 | US6596730 Phenyl urea and phenyl thiourea derivatives |
| 07/22/2003 | US6596319 Such as various cancers, by administering low molecular weight compounds of following properties: extractable from bile of an animal, stimulates monocytes and macrophages, modulates tumor necrosis factor production, not endotoxin |
| 07/22/2003 | US6596282 Treatment of chronic viral infections with M. vaccae |
| 07/22/2003 | CA2275166C Novel benzopyran derivatives |
| 07/22/2003 | CA2243274C Male contraceptive implant |
| 07/22/2003 | CA2239603C Quinolines and quinazolines useful in therapy |
| 07/17/2003 | WO2003057888A1 Cell-specific expression/replication vector |
| 07/17/2003 | WO2003057729A2 Mammal prolactin variants |
| 07/17/2003 | WO2003057725A2 Cell-permeable peptide inhibitors of the jnk signal transduction pathway |
| 07/17/2003 | WO2003057674A1 4-sulfide / sulfoxide / sulfonyl-1h-pyrazolyl derivative compounds, for use in diseases associated with the 5-ht2c receptor |
| 07/17/2003 | WO2003057671A1 Biaryl compound and use thereof |
| 07/17/2003 | WO2003057668A1 Nitrogenous cyclic ketone derivative, process for producing the same, and use |
| 07/17/2003 | WO2003057666A2 Inhibitors of dipeptidyl peptidase iv |
| 07/17/2003 | WO2003057264A1 Feminine care products for the delivery of therapeutic substances |
| 07/17/2003 | WO2003057220A1 Cyclic urea derivatives with 5-ht2c receptor activity |
| 07/17/2003 | WO2003057200A2 Compositions comprising inhibitors of dpp-iv and nep enzymes for the treatment of diabetes |
| 07/17/2003 | WO2003057196A1 Drug mixture with enhanced dissolution rate |
| 07/17/2003 | WO2003057166A2 Treatment of pain, inflammation, and inflammation-related disorders with a combination of a cyclooxygenase-2 selective inhibitor and aspirin |
| 07/17/2003 | WO2003057159A2 Psoriasin expression by breast epithelial cells |
| 07/17/2003 | WO2003057148A2 Use of biomolecular targets in the treatment and visualization of tumors |
| 07/17/2003 | WO2003057144A2 Change inhibitors of dipeptidyl peptidase iv |
| 07/17/2003 | WO2003057134A2 Specific binding agents of human angiopoietin-2 |
| 07/17/2003 | WO2003008573A3 Silencing of gene expression by sirna |
| 07/17/2003 | WO2003000896A3 POLYNUCLEOTIDES AND POLYPEPTIDES OF THE IFNα-5 GENE |
| 07/17/2003 | WO2002072626A3 Novel form of the phgpx protein as a diagnostic marker for male infertility |
| 07/17/2003 | WO2002059286A3 Adenylate cyclases |
| 07/17/2003 | WO2002046190A3 Sulfonamido ether substituted imidazoquinolines |
| 07/17/2003 | WO2001094369A3 Heterocycle derivatives and methods of use for treating anthrax infection |
| 07/17/2003 | US20030134899 Pharmaceutical combination of bicalutamide and tamoxifen for providing an anti-androgenic effect and an anti-oestrogenic effect |
| 07/17/2003 | US20030134861 Transmucosal phosphodiesterase inhibitors for the treatment of erectile dysfunction |
| 07/17/2003 | US20030134858 Treatment of inflammation associated disorders, such as arthritis, colon cancer, and Alzheimer's disease |
| 07/17/2003 | US20030134850 Hydrazinyl and nitrogen oxide pyrazoles |
| 07/17/2003 | US20030134847 New polycyclic azaindole compounds |
| 07/17/2003 | US20030134839 5-(Alkylidene-cycloalkyl)-and 5-(alkylidene-heterocyclyl)-pyrazoles |
| 07/17/2003 | US20030134836 Substituted arylamine derivatives and methods of use |
| 07/17/2003 | US20030134829 X is a ring having at least 4 atoms in the ring; K is hydrocarbyl group; Rh1 is an optional halo group; Rh2 is an optional halo group; at least one of Rh1 and Rh2 is present; Rs is any one of a sulphamate group, a phosphonate, |
| 07/17/2003 | US20030134810 Delivery of pharmacologically active agents associated with polymeric biocompatible materials. Compositions comprising a first, negatively charged pharmacologically active agent such as an oligonucleotide and a polycationic polymer such as |
| 07/17/2003 | US20030134800 Physiologically active substance in high content, suppressing the initial excess release, and achieving a stable release speed over a long period of time is provided. composition weight, (2) hydroxynaphthoic acid |
| 07/17/2003 | US20030134430 Novel amino acid sequences for human caenorhabditis elegans-like protein polypeptides |
| 07/17/2003 | US20030133969 Topical agent capable of disrupting membrane or protein conformation in a target cell, tissue or microbe; does not contain nonoxynol-9, benzalkonium chloride or menfegol |
| 07/17/2003 | US20030133964 Polymeric delivery formulations of leuprolide with improved efficacy |
| 07/17/2003 | US20030133880 Powdery pharmaceutical compositions for inhalation |
| 07/17/2003 | CA2767061A1 Specific binding agents of human angiopoietin-2 |
| 07/17/2003 | CA2472647A1 Mammal prolactin variants |
| 07/17/2003 | CA2472585A1 Drug mixture with enhanced dissolution rate |
| 07/17/2003 | CA2471951A1 Treatment of pain, inflammation, and inflammation-related disorders with a combination of a cyclooxygenase-2 selective inhibitor and aspirin |
| 07/17/2003 | CA2471885A1 4-sulfide / sulfoxide / sulfonyl-1h-pyrazolyl derivative compounds, for use in diseases associated with the 5-ht2c receptor |
| 07/17/2003 | CA2471204A1 Inhibitors of dipeptidyl peptidase iv |
| 07/17/2003 | CA2469480A1 Use of biomolecular targets in the treatment and visualization of tumors |
| 07/17/2003 | CA2467829A1 Feminine care products for the delivery of therapeutic substances |
| 07/16/2003 | EP1327887A2 Use of thiazolium compounds for preventing and reversing the formation of advanced glycosylation end products |
| 07/16/2003 | EP1326864A2 Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents |
| 07/16/2003 | EP1326822A2 Ketone compounds and compositions for cholesterol management and related uses |
| 07/16/2003 | EP1326642A2 Catecholamine pharmaceutical compositions and methods |
| 07/16/2003 | EP1326631A1 Methods for treating endocrine disorders |
| 07/16/2003 | EP1326627A1 Methods of modulating apoptosis by administration of relaxin agonists or antagonists |
| 07/16/2003 | EP1326606A2 Ep4 receptor inhibitors to treat rheumatoid arthritis |
| 07/16/2003 | EP1326604A2 Combination of at least two compounds selected from an at1-receptorantagonist or an ace inhibitor or a hmg-co-a reductase inhibitor groups |
| 07/16/2003 | EP1235579B1 Pharmaceutical compositions comprising trimegestone |
| 07/16/2003 | EP1181284B1 Diphenyl-1,2,3-thiadiazol-3-oxides, compositions and methods of use |
| 07/16/2003 | EP1076558B1 2-phenyl-1-[-(2-aminoethoxy)-benzyl -indole in combination with estrogens |
| 07/16/2003 | EP1054669B1 Use of thiadiazolo[4,3-a]pyridine derivatives |
| 07/16/2003 | EP0975354A4 Ligand/lytic peptide compositions and methods of use |
| 07/16/2003 | EP0688365B1 Fertility regulation with transforming growth factor beta |
| 07/16/2003 | CN1430624A Novel solid body forms of mesoprogestin 11-beta-[4E-(hydroxyimino methyl)-phenyl]-17-alpha-methoxy methyl-17 beta-methoxy-estra-4,9-dien-3-one |
| 07/16/2003 | CN1430610A Substituted 1-aminoalkyl-lactams compound and their use as muscarinic receptor antagonists |
| 07/16/2003 | CN1430609A Substituted 1-aminoalkyl-lactams compound and their use as muscarinic receptor antagonists |
| 07/16/2003 | CN1430597A Novel MMP-2/MMP-9 inhibitors |
| 07/16/2003 | CN1430505A Microspheres for active embolization |
| 07/16/2003 | CN1429605A Drug composition for preventing and treating prospermia and/or sexual excitation hypersensitivity |
| 07/16/2003 | CN1429596A Manufacturing process of Rujietai preparation |
| 07/16/2003 | CN1429584A Distillate for antiemetic |
| 07/16/2003 | CN1429582A Fulonggan mixture for treating vomiting of pregnancy |
| 07/16/2003 | CN1429580A Health-care food made of egg and three Chinese medicine herbs |
| 07/16/2003 | CN1429577A Medicine for treating high prolactin blood trouble |
| 07/16/2003 | CN1429567A Blood stasis removing tablet |
| 07/16/2003 | CN1429566A Dysmenorrhea pain relieving egg |
| 07/16/2003 | CN1429565A Liquid for remission and treating mastadenitis and mammary suppuration |
| 07/16/2003 | CN1429564A Miscarriage prevention tablet |
| 07/16/2003 | CN1429553A Use of centella total glycoside in manufacture of medicine |
| 07/16/2003 | CN1429548A Medicine for treating disease related to low cyclo GMP level |
| 07/16/2003 | CN1114444C Natural product capable of stimulating lactation of domestic animal |
| 07/16/2003 | CN1114437C Medicated wine |
| 07/16/2003 | CN1114423C External used liquid for treating tumour, hyperplastic surgical disease |
| 07/15/2003 | US6593357 Treating disease states in mammals that are alleviated by a protein kinase inhibitor, particularly diseases such as cancer, inflammatory disorders, restenosis, and cardiovascular disease. |
| 07/15/2003 | US6593350 For therapy of depression, obsessive compulsive disorder, panic attacks, generalized anxiety disorder, social anxiety disorder, sexual dysfunction, eating disorders, obesity, addictive disorders caused by ethanol or cocaine abuse |
| 07/15/2003 | US6593347 Nitrosated and nitrosylated nonsteroidal antiinflammatory compounds, compositions and methods of use |
| 07/15/2003 | US6593335 Disease than can be ameliorated with a potassium channel opener in a host mammal, comprising administering to the mammal in need thereof a therapeutically effective amount of the compound of claim 1; said disease is epilepsy, Raynaud's |
| 07/15/2003 | US6593332 Phosphodiesterase inhibitors; sexual disorders |
| 07/15/2003 | US6593322 Compounds and methods for modulation of estrogen receptors |
| 07/15/2003 | US6593317 Progestin therapy for maintaining amenorrhea |
| 07/15/2003 | US6593313 Co-administration of a prostaglandin and an androgenic agent in the treatment of female sexual dysfunction |
| 07/15/2003 | US6593291 Inhibition of endothelial cell proliferation inhibits neovascularization |
| 07/15/2003 | US6592893 Transdermal patch and topical compositions comprising propylnorapomorphine |
| 07/10/2003 | WO2003055991A1 Igamete recruitment and developmental competence in mammals by inhibiting the de novo sterol biosynthesis and/or promoting sterol efflux |